Medicinal Products

Tysabri

Name Tysabri
Active Substance natalizumab
Prescription na recept
Type of prescription ograničeni recept
Distribution u ljekarni
ATC Code L04AA23
Medicinal product marketed in the Croatia Da
Educational materials
for healthcare professionals
Informacije za liječnike i smjernice za liječenje, verzija 7
Obrazac za nastavak liječenja Tysabrijem, verzija 5
Obrazac za početak liječenja Tysabrijem, verzija 5
Obrazac za trajni prekid liječenja Tysabrijem, verzija 3
Educational materials
for patients / caregivers
Kartica s upozorenjem za bolesnika, verzija 5

Note

The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri

The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm

Direct Healthcare Professional Communication

Name Date Download
Pismo zdravstvenim radnicima o ažuriranju mjera minimizacije rizika od PML-a za Tysabri (natalizumab) 16.03.2016 Biogen Idec Limited
Back